Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEN NASDAQ:ORIC NASDAQ:PHAR NASDAQ:SANA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$2.25-8.7%$2.60$1.29▼$3.23$232.60M2.74517,081 shs738,198 shsORICOric Pharmaceuticals$7.72-14.1%$9.66$7.23▼$14.93$929.59M1.041.32 million shs3.62 million shsPHARPharming Group$12.60-3.8%$15.33$9.54▼$21.34$917.42M-0.0416,721 shs11,155 shsSANASana Biotechnology$3.21-0.2%$3.23$2.10▼$6.55$918.36M2.144.13 million shs3.40 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen-6.46%-12.14%-9.23%+23.00%+65.10%ORICOric Pharmaceuticals+6.27%+7.93%-8.09%-33.53%+8.72%PHARPharming Group+0.85%+3.97%-22.85%-14.94%+20.24%SANASana Biotechnology-2.73%+4.56%-1.83%-18.32%+48.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$2.25-8.7%$2.60$1.29▼$3.23$232.60M2.74517,081 shs738,198 shsORICOric Pharmaceuticals$7.72-14.1%$9.66$7.23▼$14.93$929.59M1.041.32 million shs3.62 million shsPHARPharming Group$12.60-3.8%$15.33$9.54▼$21.34$917.42M-0.0416,721 shs11,155 shsSANASana Biotechnology$3.21-0.2%$3.23$2.10▼$6.55$918.36M2.144.13 million shs3.40 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen-6.46%-12.14%-9.23%+23.00%+65.10%ORICOric Pharmaceuticals+6.27%+7.93%-8.09%-33.53%+8.72%PHARPharming Group+0.85%+3.97%-22.85%-14.94%+20.24%SANASana Biotechnology-2.73%+4.56%-1.83%-18.32%+48.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGENCompugen 2.80Moderate Buy$5.00122.72% UpsideORICOric Pharmaceuticals 2.73Moderate Buy$19.36150.99% UpsidePHARPharming Group 2.40Hold$38.33204.23% UpsideSANASana Biotechnology 2.67Moderate Buy$9.50196.41% UpsideCurrent Analyst Ratings BreakdownLatest CGEN, ORIC, SANA, and PHAR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026ORICOric Pharmaceuticals Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/21/2026CGENCompugen Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$13.00 ➝ $5.005/15/2026ORICOric Pharmaceuticals The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$15.005/11/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)5/11/2026SANASana Biotechnology Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.005/5/2026ORICOric Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$17.00 ➝ $16.005/1/2026SANASana Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)4/21/2026ORICOric Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CGENCompugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/14/2026SANASana Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGENCompugen$72.66M2.92$0.32 per share7.04$1.09 per share2.06ORICOric PharmaceuticalsN/AN/AN/AN/A$3.90 per shareN/APHARPharming Group$376.13M2.37$0.19 per share64.77$3.95 per share3.19SANASana BiotechnologyN/AN/AN/AN/A$0.60 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGENCompugen$35.34M$0.376.42N/AN/A47.97%47.72%27.51%8/5/2026 (Estimated)ORICOric Pharmaceuticals-$129.47M-$1.44N/AN/AN/AN/A-35.33%-33.31%8/11/2026 (Estimated)PHARPharming Group$2.85M$0.1678.6419.38N/A3.30%4.64%2.55%7/30/2026 (Estimated)SANASana Biotechnology-$244.17M-$0.93N/AN/AN/AN/A-108.01%-40.68%8/10/2026 (Estimated)Latest CGEN, ORIC, SANA, and PHAR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026CGENCompugen-$0.07-$0.08-$0.01-$0.08$1.57 million$2.18 million5/11/2026Q1 2026SANASana Biotechnology-$0.15-$0.14+$0.01-$0.17N/AN/A5/7/2026Q1 2026PHARPharming Group$0.05-$0.07-$0.12-$0.07$92.06 million$72.45 million5/4/2026Q1 2026ORICOric Pharmaceuticals-$0.31-$0.34-$0.03-$0.34N/AN/A3/12/2026Q4 2025PHARPharming Group$0.15$0.07-$0.08$0.07$111.76 million$106.50 million3/3/2026Q4 2025SANASana Biotechnology-$0.13-$0.16-$0.03-$0.21N/AN/A3/2/2026Q4 2025CGENCompugen$0.05$0.60+$0.55$0.60$14.30 million$67.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGENCompugenN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGENCompugenN/A6.236.23ORICOric PharmaceuticalsN/A16.3316.33PHARPharming Group0.352.632.06SANASana BiotechnologyN/A1.291.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGENCompugen12.22%ORICOric Pharmaceuticals95.05%PHARPharming Group0.03%SANASana Biotechnology88.23%Insider OwnershipCompanyInsider OwnershipCGENCompugen9.50%ORICOric Pharmaceuticals5.70%PHARPharming Group2.07%SANASana Biotechnology25.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGENCompugen7094.55 million85.57 millionOptionableORICOric Pharmaceuticals80103.52 million97.62 millionOptionablePHARPharming Group28070.62 million69.16 millionNot OptionableSANASana Biotechnology380278.29 million207.61 millionOptionableCGEN, ORIC, SANA, and PHAR HeadlinesRecent News About These CompaniesWall Street Zen Upgrades Sana Biotechnology (NASDAQ:SANA) to "Hold"May 30 at 1:34 AM | americanbankingnews.comSana Biotechnology to Present at June 2026 Investor ConferencesMay 27, 2026 | globenewswire.comSana Biotechnology Raises $69 Million Through Equity OfferingMay 15, 2026 | tipranks.comSana Biotechnology Shares Fall on Sale of $69 Million in Shares Through At-The-Market FacilityMay 15, 2026 | marketwatch.comSana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) FacilityMay 15, 2026 | globenewswire.comSana Biotechnology (SANA) Receives a Buy from WedbushMay 14, 2026 | theglobeandmail.comBank of America Securities Keeps Their Buy Rating on Sana Biotechnology (SANA)May 13, 2026 | theglobeandmail.comSana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell ...May 13, 2026 | markets.businessinsider.comSana Biotechnology, Inc. (SANA) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comSana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPsMay 12, 2026 | globenewswire.comSana: Q1 Earnings SnapshotMay 12, 2026 | finance.yahoo.comSana Biotechnology Reports First Quarter 2026 Financial Results and Business UpdatesMay 12, 2026 | markets.businessinsider.comRodman & Renshaw Begins Coverage on Sana Biotechnology (NASDAQ:SANA)May 11, 2026 | marketbeat.comSana Biotechnology (NASDAQ:SANA) Rating Increased to Sell at Wall Street ZenMay 9, 2026 | marketbeat.comSana Biotechnology (SANA) Projected to Post Quarterly Earnings on ThursdayMay 7, 2026 | marketbeat.comSana Biotechnology to Present at the BofA Securities 2026 Healthcare ConferenceMay 5, 2026 | globenewswire.comSana to present in vivo CAR T data as Janux drops trialApril 28, 2026 | msn.comSana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual MeetingApril 27, 2026 | globenewswire.comSana Biotech (SANA), Mayo Clinic Partner to Advance Cell Therapy for Type 1 DiabetesApril 27, 2026 | finance.yahoo.comSana Biotechnology Rebalances Board Classes With Director ShiftApril 24, 2026 | tipranks.comAssessing Sana Biotechnology (SANA) Valuation After Mayo Clinic Partnership And Equity InvestmentApril 23, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesApple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 2026SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?By Chris Markoch | May 22, 2026Is Costco Preparing Another Special Dividend This Year?By Dan Schmidt | May 8, 2026The Great SPR Arbitrage: An Oil Market Glitch Fuels Sector GainsBy Jeffrey Neal Johnson | May 14, 2026Why Lam Research Still Looks Like a Buy After a 300% RallyBy Sam Quirke | May 7, 2026CGEN, ORIC, SANA, and PHAR Company DescriptionsCompugen NASDAQ:CGEN$2.24 -0.22 (-8.74%) As of 02:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Oric Pharmaceuticals NASDAQ:ORIC$7.72 -1.27 (-14.09%) As of 02:54 PM Eastern This is a fair market value price provided by Massive. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Pharming Group NASDAQ:PHAR$12.60 -0.50 (-3.82%) As of 02:50 PM Eastern This is a fair market value price provided by Massive. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.Sana Biotechnology NASDAQ:SANA$3.20 -0.01 (-0.16%) As of 02:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dollar General Signals Reversal With 60% Rebound Potential Kohl's Stock Soars After Better-Than-Feared Quarter Credo Technologies Paved a Path to a $300 Price Point MGM Buyout: The House Doesn't Always Win Alphabet's $80 Billion Offering: Worrisome Dilution or AI Confidence? FirstCash Turns Pawn Into a Growth Machine HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead? Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
